Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 11(1): 7730, 2021 04 08.
Artigo em Inglês | MEDLINE | ID: mdl-33833328

RESUMO

The pigment cell-specific protein PMEL forms a functional amyloid matrix in melanosomes onto which the pigment melanin is deposited. The amyloid core consists of a short proteolytic fragment, which we have termed the core-amyloid fragment (CAF) and perhaps additional parts of the protein, such as the PKD domain. A highly O-glycosylated repeat (RPT) domain also derived from PMEL proteolysis associates with the amyloid and is necessary to establish the sheet-like morphology of the assemblies. Excluded from the aggregate is the regulatory N-terminus, which nevertheless must be linked in cis to the CAF in order to drive amyloid formation. The domain is then likely cleaved away immediately before, during, or immediately after the incorporation of a new CAF subunit into the nascent amyloid. We had previously identified a 21 amino acid long region, which mediates the regulatory activity of the N-terminus towards the CAF. However, many mutations in the respective segment caused misfolding and/or blocked PMEL export from the endoplasmic reticulum, leaving their phenotype hard to interpret. Here, we employ a saturating mutagenesis approach targeting the motif at single amino acid resolution. Our results confirm the critical nature of the PMEL N-terminal region and identify several residues essential for PMEL amyloidogenesis.


Assuntos
Aminoácidos/química , Domínios Proteicos , Antígeno gp100 de Melanoma/química , Sequência de Aminoácidos , Retículo Endoplasmático/metabolismo , Humanos , Melanossomas/metabolismo , Mutação , Dobramento de Proteína , Transporte Proteico , Frações Subcelulares/metabolismo , Antígeno gp100 de Melanoma/metabolismo
2.
Sci Rep ; 9(1): 6101, 2019 04 15.
Artigo em Inglês | MEDLINE | ID: mdl-30988362

RESUMO

PMEL is a pigment cell-specific protein that forms a functional amyloid matrix in melanosomes. The matrix consists of well-separated fibrillar sheets on which the pigment melanin is deposited. Using electron tomography, we demonstrate that this sheet architecture is governed by the PMEL repeat (RPT) domain, which associates with the amyloid as an accessory proteolytic fragment. Thus, the RPT domain is dispensable for amyloid formation as such but shapes the morphology of the matrix, probably in order to maximize the surface area available for pigment adsorption. Although the primary amino acid sequence of the RPT domain differs vastly among various vertebrates, we show that it is a functionally conserved, interchangeable module. RPT domains of all species are predicted to be very highly O-glycosylated, which is likely the common defining feature of this domain. O-glycosylation is indeed essential for RPT domain function and the establishment of the PMEL sheet architecture. Thus, O-glycosylation, not amino acid sequence, appears to be the major factor governing the characteristic PMEL amyloid morphology.


Assuntos
Proteínas Amiloidogênicas/química , Melanossomas/metabolismo , Domínios Proteicos , Antígeno gp100 de Melanoma/química , Animais , Linhagem Celular Tumoral , Galinhas , Colubridae , Glicosilação , Humanos , Camundongos , Polissacarídeos/química , Xenopus laevis , Peixe-Zebra
3.
Hum Mol Genet ; 28(8): 1298-1311, 2019 04 15.
Artigo em Inglês | MEDLINE | ID: mdl-30561643

RESUMO

Pigmentary glaucoma (PG) is a common glaucoma subtype that results from release of pigment from the iris, called pigment dispersion syndrome (PDS), and its deposition throughout the anterior chamber of the eye. Although PG has a substantial heritable component, no causative genes have yet been identified. We used whole exome sequencing of two independent pedigrees to identify two premelanosome protein (PMEL) variants associated with heritable PDS/PG. PMEL encodes a key component of the melanosome, the organelle essential for melanin synthesis, storage and transport. Targeted screening of PMEL in three independent cohorts (n = 394) identified seven additional PDS/PG-associated non-synonymous variants. Five of the nine variants exhibited defective processing of the PMEL protein. In addition, analysis of PDS/PG-associated PMEL variants expressed in HeLa cells revealed structural changes to pseudomelanosomes indicating altered amyloid fibril formation in five of the nine variants. Introduction of 11-base pair deletions to the homologous pmela in zebrafish by the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 method caused profound pigmentation defects and enlarged anterior segments in the eye, further supporting PMEL's role in ocular pigmentation and function. Taken together, these data support a model in which missense PMEL variants represent dominant negative mutations that impair the ability of PMEL to form functional amyloid fibrils. While PMEL mutations have previously been shown to cause pigmentation and ocular defects in animals, this research is the first report of mutations in PMEL causing human disease.


Assuntos
Glaucoma de Ângulo Aberto/genética , Antígeno gp100 de Melanoma/genética , Antígeno gp100 de Melanoma/fisiologia , Adulto , Amiloide/metabolismo , Animais , Feminino , Células HeLa , Humanos , Iris/metabolismo , Masculino , Melanossomas/genética , Pessoa de Meia-Idade , Mutação de Sentido Incorreto/genética , Linhagem , Pigmentação/genética , Sequenciamento do Exoma/métodos , Adulto Jovem , Peixe-Zebra
4.
J Immunol ; 201(7): 1875-1888, 2018 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-30135181

RESUMO

Cancer immunotherapy has been flourishing in recent years with remarkable clinical success. But as more patients are treated, a shadow is emerging that has haunted other cancer therapies: tumors develop resistance. Resistance is often caused by defects in the MHC class I Ag presentation pathway critical for CD8 T cell-mediated tumor clearance. TAP and tapasin, both key players in the pathway, are frequently downregulated in human cancers, correlating with poor patient survival. Reduced dependence on these factors may promote vaccine efficiency by limiting immune evasion. In this study, we demonstrate that PMEL209-217, a promising phase 3 trial-tested antimelanoma vaccine candidate, is robustly presented by various TAP- and/or tapasin-deficient cell lines. This striking characteristic may underlie its potency as a vaccine. Surprisingly, cytosolic proteasomes generate the peptide even for TAP-independent presentation, whereas tripeptidyl peptidase 2 (TPP2) efficiently degrades the epitope. Consequently, inhibiting TPP2 substantially boosts PMEL209-217 presentation, suggesting a possible strategy to improve the therapeutic efficacy of the vaccine.


Assuntos
Linfócitos T CD8-Positivos/imunologia , Imunoterapia Adotiva/métodos , Melanoma/imunologia , Vacinas/imunologia , Aminopeptidases/metabolismo , Apresentação de Antígeno , Linfócitos T CD8-Positivos/transplante , Linhagem Celular Tumoral , Citosol/metabolismo , Dipeptidil Peptidases e Tripeptidil Peptidases/metabolismo , Epitopos de Linfócito T/imunologia , Epitopos de Linfócito T/metabolismo , Antígeno HLA-A2/metabolismo , Humanos , Evasão da Resposta Imune , Proteínas de Membrana Transportadoras/genética , Oligopeptídeos/genética , Serina Endopeptidases/metabolismo , Antígeno gp100 de Melanoma/imunologia , Antígeno gp100 de Melanoma/metabolismo
5.
Int J Med Microbiol ; 308(1): 185-196, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29126745

RESUMO

Autophagy is an evolutionarily ancient and highly conserved eukaryotic mechanism that targets cytoplasmic material for degradation. Autophagic flux involves the formation of autophagosomes and their degradation by lysosomes. The process plays a crucial role in maintaining cellular homeostasis and responds to various environmental conditions. While autophagy had previously been thought to be a non-selective process, it is now clear that it can also selectively target cellular organelles, such as mitochondria (referred to as mitophagy) and/or invading pathogens (referred to as xenophagy). Selective autophagy is characterized by specific substrate recognition and requires distinct cellular adaptor proteins. Here we review xenophagic mechanisms involved in the recognition and autolysosomal or autophagolysosomal degradation of different intracellular bacteria. In this context, we also discuss a recently discovered cellular self-defense pathway, termed mito-xenophagy, which occurs during bacterial infection of dendritic cells and depends on a TNF-α-mediated metabolic switch from oxidative phosphorylation to glycolysis.


Assuntos
Autofagossomos/microbiologia , Autofagia , Bactérias/imunologia , Bactérias/patogenicidade , Lisossomos/microbiologia , Animais , Autofagossomos/metabolismo , Citoplasma/microbiologia , Células Dendríticas/metabolismo , Células Dendríticas/microbiologia , Humanos , Lisossomos/metabolismo , Mitocôndrias/metabolismo , Mitocôndrias/microbiologia
6.
Sci Rep ; 7: 44064, 2017 03 08.
Artigo em Inglês | MEDLINE | ID: mdl-28272432

RESUMO

PMEL is a pigment cell protein that forms physiological amyloid in melanosomes. Many amyloids and/or their oligomeric precursors are toxic, causing or contributing to severe, incurable diseases including Alzheimer's and prion diseases. Striking similarities in intracellular formation pathways between PMEL and various pathological amyloids including Aß and PrPSc suggest PMEL is an excellent model system to study endocytic amyloid. Learning how PMEL fibrils assemble without apparent toxicity may help developing novel therapies for amyloid diseases. Here we identify the critical PMEL domain that forms the melanosomal amyloid core (CAF). An unbiased alanine-scanning screen covering the entire region combined with quantitative electron microscopy analysis of the full set of mutants uncovers numerous essential residues. Many of these rely on aromaticity for function suggesting a role for π-stacking in melanosomal amyloid assembly. Various mutants are defective in amyloid nucleation. This extensive data set informs the first structural model of the CAF and provides insights into how the melanosomal amyloid core forms.


Assuntos
Proteínas Amiloidogênicas/metabolismo , Melanossomas/metabolismo , Antígeno gp100 de Melanoma/metabolismo , Proteínas Amiloidogênicas/química , Linhagem Celular , Humanos , Antígeno gp100 de Melanoma/química
7.
J Immunol ; 195(11): 5482-94, 2015 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-26519531

RESUMO

The transporter associated with Ag processing (TAP) translocates proteasomally derived cytosolic peptides into the endoplasmic reticulum. TAP is a central component of the peptide-loading complex (PLC), to which tapasin (TPN) recruits MHC class I (MHC I) and accessory chaperones. The PLC functions to facilitate and optimize MHC I-mediated Ag presentation. The heterodimeric peptide transporter consists of two homologous subunits, TAP1 and TAP2, each of which contains an N-terminal domain (N-domain) in addition to a conserved transmembrane (TM) core segment. Each N-domain binds to the TM region of a single TPN molecule, which recruits one MHC I molecule to TAP1 and/or TAP2. Although both N-domains act as TPN-docking sites, various studies suggest a functional asymmetry within the PLC resulting in greater significance of the TAP2/TPN interaction for MHC loading. In this study, we demonstrate that the leucine-rich hydrophobic sequence stretches (with the central leucine residues L20 and L66) in the first and second TM helix of TAP2 form a functional unit acting as a docking site for optimal TPN/MHC I recruitment, whereas three distinct highly conserved arginine and/or aspartate residues inside or flanking these TM helices are dispensable. Moreover, we show that the physical interaction between TAP2 and TPN is disrupted by benzene, a compound known to interfere with hydrophobic interactions, such as those between pairing leucine zippers. No such effects were observed for the TAP1/TAP2 interaction or the complex formation between TPN and MHC I. We propose that TAP/TPN complex formation is driven by hydrophobic interactions via leucine zipper-like motifs.


Assuntos
Transportadores de Cassetes de Ligação de ATP/metabolismo , Proteínas de Membrana Transportadoras/metabolismo , Complexos Multiproteicos/ultraestrutura , Membro 3 da Subfamília B de Transportadores de Cassetes de Ligação de ATP , Transportadores de Cassetes de Ligação de ATP/ultraestrutura , Benzeno/química , Sítios de Ligação/imunologia , Transporte Biológico/imunologia , Linhagem Celular , Retículo Endoplasmático/imunologia , Antígenos de Histocompatibilidade Classe I/imunologia , Humanos , Interações Hidrofóbicas e Hidrofílicas , Zíper de Leucina/efeitos dos fármacos , Zíper de Leucina/genética , Proteínas de Membrana Transportadoras/ultraestrutura , Complexos Multiproteicos/efeitos dos fármacos , Complexos Multiproteicos/metabolismo , Ligação Proteica/imunologia , Estrutura Terciária de Proteína
8.
J Immunol ; 192(5): 2480-94, 2014 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-24501197

RESUMO

The TAP translocates peptide Ags into the lumen of the endoplasmic reticulum for loading onto MHC class I molecules. MHC class I acquires its peptide cargo in the peptide loading complex, an oligomeric complex that the chaperone tapasin organizes by bridging TAP to MHC class I and recruiting accessory molecules such as ERp57 and calreticulin. Three tapasin binding sites on TAP have been described, two of which are located in the N-terminal domains of TAP1 and TAP2. The third binding site is present in the core transmembrane (TM) domain of TAP1 and is used only by the unassembled subunits. Tapasin is required to promote TAP stability, but through which binding site(s) it is acting is unknown. In particular, the role of tapasin binding to the core TM domain of TAP1 single chains is mysterious because this interaction is lost upon TAP2 association. In this study, we map the respective binding site in TAP1 to the polar face of the amphipathic TM helix TM9 and identify key residues that are essential to establish the interaction. We find that this interaction is dispensable for the peptide transport function but essential to achieve full stability of human TAP1. The interaction is also required for proper heterodimerization of the transporter. Based on similar results obtained using TAP mutants that lack tapasin binding to either N-terminal domain, we conclude that all three tapasin-binding sites in TAP cooperate to achieve high transporter stability and efficient heterodimerization.


Assuntos
Transportadores de Cassetes de Ligação de ATP/imunologia , Antígenos de Histocompatibilidade Classe I/imunologia , Multimerização Proteica/imunologia , Membro 2 da Subfamília B de Transportadores de Cassetes de Ligação de ATP , Membro 3 da Subfamília B de Transportadores de Cassetes de Ligação de ATP , Transportadores de Cassetes de Ligação de ATP/química , Transportadores de Cassetes de Ligação de ATP/genética , Transportadores de Cassetes de Ligação de ATP/metabolismo , Sítios de Ligação , Calreticulina/química , Calreticulina/genética , Calreticulina/imunologia , Calreticulina/metabolismo , Linhagem Celular Tumoral , Antígenos de Histocompatibilidade Classe I/química , Antígenos de Histocompatibilidade Classe I/genética , Antígenos de Histocompatibilidade Classe I/metabolismo , Humanos , Proteínas de Membrana Transportadoras/química , Proteínas de Membrana Transportadoras/genética , Proteínas de Membrana Transportadoras/imunologia , Isomerases de Dissulfetos de Proteínas/genética , Isomerases de Dissulfetos de Proteínas/imunologia , Estabilidade Proteica , Estrutura Secundária de Proteína
9.
Mol Biol Cell ; 24(7): 964-81, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23389629

RESUMO

PMEL (also called Pmel17 or gp100) is a melanocyte/melanoma-specific glycoprotein that plays a critical role in melanosome development by forming a fibrillar amyloid matrix in the organelle for melanin deposition. Although ultimately not a component of mature fibrils, the PMEL N-terminal region (NTR) is essential for their formation. By mutational analysis we establish a high-resolution map of this domain in which sequence elements and functionally critical residues are assigned. We show that the NTR functions in cis to drive the aggregation of the downstream polycystic kidney disease (PKD) domain into a melanosomal core matrix. This is essential to promote in trans the stabilization and terminal proteolytic maturation of the repeat (RPT) domain-containing MαC units, precursors of the second fibrillogenic fragment. We conclude that during melanosome biogenesis the NTR controls the hierarchical assembly of melanosomal fibrils.


Assuntos
Amiloide/metabolismo , Melaninas/metabolismo , Melanossomas/metabolismo , Antígeno gp100 de Melanoma/metabolismo , Sequência de Aminoácidos , Amiloide/ultraestrutura , Ácido Aspártico/genética , Ácido Aspártico/metabolismo , Sítios de Ligação/genética , Western Blotting , Linhagem Celular Tumoral , Humanos , Melanoma/genética , Melanoma/metabolismo , Melanoma/patologia , Melanossomas/ultraestrutura , Microscopia Eletrônica de Transmissão , Microscopia de Fluorescência , Dados de Sequência Molecular , Mutação , Organelas/metabolismo , Organelas/ultraestrutura , Prolina/genética , Prolina/metabolismo , Transporte Proteico , Proteólise , Homologia de Sequência de Aminoácidos , Triptofano/genética , Triptofano/metabolismo , Antígeno gp100 de Melanoma/química , Antígeno gp100 de Melanoma/genética
10.
J Biol Chem ; 287(37): 31172-84, 2012 Sep 07.
Artigo em Inglês | MEDLINE | ID: mdl-22829594

RESUMO

Although the human peptide-loading complex (PLC) is required for optimal major histocompatibility complex class I (MHC I) antigen presentation, its composition is still incompletely understood. The ratio of the transporter associated with antigen processing (TAP) and MHC I to tapasin, which is responsible for MHC I recruitment and peptide binding optimization, is particularly critical for modeling of the PLC. Here, we characterized the stoichiometry of the human PLC using both biophysical and biochemical approaches. By means of single-molecule pulldown (SiMPull), we determined a TAP/tapasin ratio of 1:2, consistent with previous studies of insect-cell microsomes, rat-human chimeric cells, and HeLa cells expressing truncated TAP subunits. We also report that the tapasin/MHC I ratio varies, with the PLC population comprising both 2:1 and 2:2 complexes, based on mutational and co-precipitation studies. The MHC I-saturated PLC may be particularly prevalent among peptide-selective alleles, such as HLA-C4. Additionally, MHC I association with the PLC increases when its peptide supply is reduced by inhibiting the proteasome or by blocking TAP-mediated peptide transport using viral inhibitors. Taken together, our results indicate that the composition of the human PLC varies under normal conditions and dynamically adapts to alterations in peptide supply that may arise during viral infection. These findings improve our understanding of the quality control of MHC I peptide loading and may aid the structural and functional modeling of the human PLC.


Assuntos
Apresentação de Antígeno/fisiologia , Antígenos HLA-C/imunologia , Proteínas de Membrana Transportadoras/imunologia , Modelos Imunológicos , Complexos Multiproteicos/imunologia , Peptídeos/imunologia , Animais , Antígenos HLA-C/genética , Antígenos HLA-C/metabolismo , Células HeLa , Humanos , Proteínas de Membrana Transportadoras/genética , Proteínas de Membrana Transportadoras/metabolismo , Complexos Multiproteicos/genética , Complexos Multiproteicos/metabolismo , Mutação , Peptídeos/genética , Peptídeos/metabolismo , Ratos
11.
Eur J Immunol ; 42(6): 1417-28, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22678898

RESUMO

Antitumor cytolytic T lymphocytes (CTLs) recognize peptides derived from cellular proteins and presented on MHC class I. One category of peptides recognized by these CTLs is derived from proteins encoded by "cancer-germline" genes, which are specifically expressed in tumors, and therefore represent optimal targets for cancer immunotherapy. Here, we identify an antigenic peptide, which is derived from the MAGE-A1-encoded protein (160-169) and presented to CTLs by HLA-B*44:02. Although this peptide is encoded by MAGE-A1, processed endogenously and presented by tumor cells, the corresponding synthetic peptide is hardly able to sensitize target cells to CTL recognition when pulsed exogenously. Endogenous processing and presentation of this peptide is strictly dependent on the presence of tapasin, which is believed to help peptide loading by stabilizing a peptide-receptive form of HLA-B*44:02. Exogenous loading of the peptide can be dramatically improved by paraformaldehyde fixation of surface molecules or by peptide loading at acidic pH. Either strategy allows efficient exogenous loading of the peptide, presumably by generating or stabilizing a peptide-receptive, empty conformation of the HLA. Altogether, our results indicate a potential drawback of short peptide-based vaccination strategies and offer possible solutions regarding the use of problematic epitopes such as the one described here.


Assuntos
Antígeno HLA-B44/imunologia , Antígenos Específicos de Melanoma/imunologia , Proteínas de Membrana Transportadoras/fisiologia , Linfócitos T Citotóxicos/imunologia , Animais , Apresentação de Antígeno , Células COS , Linhagem Celular Tumoral , Chlorocebus aethiops , Humanos , Concentração de Íons de Hidrogênio
12.
Yale J Biol Med ; 84(4): 371-80, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22180675

RESUMO

Cancer accounts for about every fourth death in the United States, with approximately 1,500 people dying each day as a result of this disease. Despite some progress in the last decades, these numbers alone undoubtedly demonstrate the urgent need for new and more efficient treatments. Immunotherapy aims to activate an efficient immune response against tumors or even prevent cancers from occurring in the first place. It is a growing field currently flourishing with several successful trials, some of which have led to the recent approval of new anti-cancer drugs by the Food and Drug Administration (FDA). This review addresses the manifold strategies that immunotherapy has taken in the past and discusses the most recent achievements in the field.


Assuntos
Sistema Imunitário/imunologia , Imunoterapia/métodos , Neoplasias/imunologia , Neoplasias/terapia , Animais , Apresentação de Antígeno/imunologia , Antígenos de Histocompatibilidade Classe I/imunologia , Humanos , Evasão da Resposta Imune/imunologia , Neoplasias/prevenção & controle , Neoplasias/radioterapia
13.
Proc Natl Acad Sci U S A ; 108(12): 4956-61, 2011 Mar 22.
Artigo em Inglês | MEDLINE | ID: mdl-21383159

RESUMO

UDP-glucose:glycoprotein glucosyltransferase 1 (UGT1) serves as a folding sensor in the calnexin/calreticulin glycoprotein quality control cycle. UGT1 recognizes disordered or hydrophobic patches near asparagine-linked nonglucosylated glycans in partially misfolded glycoproteins and reglucosylates them, returning folding intermediates to the cycle. In this study, we examine the contribution of the UGT1-regulated quality control mechanism to MHC I antigen presentation. Using UGT1-deficient mouse embryonic fibroblasts reconstituted or not with UGT1, we show that, although formation of the peptide loading complex is unaffected by the absence of UGT1, the surface level of MHC class I molecules is reduced, MHC class I maturation and assembly are delayed, and peptide selection is impaired. Most strikingly, we show using purified soluble components that UGT1 preferentially recognizes and reglucosylates MHC class I molecules associated with a suboptimal peptide. Our data suggest that, in addition to the extensively studied tapasin-mediated quality control mechanism, UGT1 adds a new level of control in the MHC class I antigen presentation pathway.


Assuntos
Apresentação de Antígeno/imunologia , Regulação da Expressão Gênica/imunologia , Glucosiltransferases/imunologia , Antígenos de Histocompatibilidade Classe I/imunologia , Peptídeos/imunologia , Dobramento de Proteína , Animais , Apresentação de Antígeno/genética , Linhagem Celular , Regulação da Expressão Gênica/genética , Glucosiltransferases/genética , Glucosiltransferases/metabolismo , Antígenos de Histocompatibilidade Classe I/biossíntese , Antígenos de Histocompatibilidade Classe I/genética , Humanos , Proteínas de Membrana Transportadoras/genética , Proteínas de Membrana Transportadoras/imunologia , Proteínas de Membrana Transportadoras/metabolismo , Camundongos , Camundongos Mutantes , Peptídeos/genética , Peptídeos/metabolismo
14.
J Biol Chem ; 286(13): 10983-97, 2011 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-21321113

RESUMO

High risk human Papillomavirus (HPV) types are the major causative agents of cervical cancer. Reduced expression of major histocompatibility complex class I (MHC I) on HPV-infected cells might be responsible for insufficient T cell response and contribute to HPV-associated malignancy. The viral gene product required for subversion of MHC I synthesis is the E7 oncoprotein. Although it has been suggested that high and low risk HPVs diverge in their ability to dysregulate MHC I expression, it is not known what sequence determinants of HPV-E7 are responsible for this important functional difference. To investigate this, we analyzed the capability to affect MHC I of a set of chimeric E7 variants containing sequence elements from either high risk HPV16 or low risk HPV11. HPV16-E7, but not HPV11-E7, causes significant diminution of mRNA synthesis and surface presentation of MHC I, which depend on histone deacetylase activity. Our experiments demonstrate that the C-terminal region within the zinc finger domain of HPV-E7 is responsible for the contrasting effects of HPV11- and HPV16-E7 on MHC I. By using different loss- and gain-of-function mutants of HPV11- and HPV16-E7, we identify for the first time a residue variation at position 88 that is highly critical for HPV16-E7-mediated suppression of MHC I. Furthermore, our studies suggest that residues at position 78, 80, and 88 build a minimal functional unit within HPV16-E7 required for binding and histone deacetylase recruitment to the MHC I promoter. Taken together, our data provide new insights into how high risk HPV16-E7 dysregulates MHC I for immune evasion.


Assuntos
Regulação da Expressão Gênica , Antígenos de Histocompatibilidade Classe I/biossíntese , Papillomavirus Humano 16/metabolismo , Evasão da Resposta Imune , Proteínas E7 de Papillomavirus/metabolismo , RNA Mensageiro/biossíntese , Células HEK293 , Antígenos de Histocompatibilidade Classe I/genética , Antígenos de Histocompatibilidade Classe I/imunologia , Histona Desacetilases/genética , Histona Desacetilases/imunologia , Histona Desacetilases/metabolismo , Papillomavirus Humano 11/genética , Papillomavirus Humano 11/imunologia , Papillomavirus Humano 11/metabolismo , Papillomavirus Humano 16/genética , Papillomavirus Humano 16/imunologia , Humanos , Proteínas Oncogênicas Virais/genética , Proteínas Oncogênicas Virais/imunologia , Proteínas Oncogênicas Virais/metabolismo , Proteínas E7 de Papillomavirus/genética , Proteínas E7 de Papillomavirus/imunologia , Regiões Promotoras Genéticas/genética , Regiões Promotoras Genéticas/imunologia , Estrutura Terciária de Proteína , RNA Mensageiro/genética , RNA Mensageiro/imunologia , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/imunologia , Proteínas Recombinantes de Fusão/metabolismo
15.
J Biol Chem ; 286(11): 9321-37, 2011 Mar 18.
Artigo em Inglês | MEDLINE | ID: mdl-21247888

RESUMO

Pmel17 is a melanocyte/melanoma-specific protein that traffics to melanosomes where it forms a fibrillar matrix on which melanin gets deposited. Before being cleaved into smaller fibrillogenic fragments the protein undergoes processing by proprotein convertases, a class of serine proteases that typically recognize the canonical motif RX(R/K)R↓. The current model of Pmel17 maturation states that this processing step occurs in melanosomes, but in light of recent reports this issue has become controversial. We therefore addressed this question by thoroughly assessing the processing kinetics of either wild-type Pmel17 or a secreted soluble Pmel17 derivative. Our results demonstrate clearly that processing of Pmel17 occurs during secretion and that it does not require entry of the protein into the endocytic system. Strikingly, processing proceeds even in the presence of the secretion inhibitor monensin, suggesting that Pmel17 is an exceptionally good substrate. In line with this, we find that newly synthesized surface Pmel17 is already quantitatively cleaved. Moreover, we demonstrate that Pmel17 function is independent of the sequence identity of its unconventional proprotein convertase-cleavage motif that lacks arginine in P4 position. The data alter the current view of Pmel17 maturation and suggest that the multistep processing of Pmel17 begins with an early cleavage during secretion that primes the protein for later functional processing.


Assuntos
Endocitose/fisiologia , Melanossomas/metabolismo , Serina Endopeptidases/metabolismo , Antígeno gp100 de Melanoma/metabolismo , Motivos de Aminoácidos , Linhagem Celular Tumoral , Humanos , Melanossomas/genética , Serina Endopeptidases/genética , Antígeno gp100 de Melanoma/genética
16.
J Biol Chem ; 285(21): 16166-83, 2010 May 21.
Artigo em Inglês | MEDLINE | ID: mdl-20231267

RESUMO

Pmel17 is a melanocyte/melanoma-specific protein that subcellularly localizes to melanosomes, where it forms a fibrillar matrix that serves for the sequestration of potentially toxic reaction intermediates of melanin synthesis and deposition of the pigment. As a key factor in melanosomal biogenesis, understanding intracellular trafficking and processing of Pmel17 is of central importance to comprehend how these organelles are formed, how they mature, and how they function in the cell. Using a series of deletion and missense mutants of Pmel17, we are able to show that the integrity of the junction between the N-terminal region and the polycystic kidney disease-like domain is highly crucial for endoplasmic reticulum export, subcellular targeting, and fibril formation by Pmel17 and thus for establishing functional melanosomes.


Assuntos
Retículo Endoplasmático/metabolismo , Melaninas/metabolismo , Melanossomas/metabolismo , Glicoproteínas de Membrana/metabolismo , Linhagem Celular Tumoral , Retículo Endoplasmático/genética , Humanos , Melaninas/genética , Melanossomas/genética , Glicoproteínas de Membrana/genética , Mutação de Sentido Incorreto , Estrutura Terciária de Proteína , Transporte Proteico/fisiologia , Antígeno gp100 de Melanoma
17.
J Immunol ; 184(6): 2985-98, 2010 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-20164418

RESUMO

The function of the peptide-loading complex (PLC) is to facilitate loading of MHC class I (MHC I) molecules with antigenic peptides in the endoplasmic reticulum and to drive the selection of these ligands toward a set of high-affinity binders. When the PLC fails to perform properly, as frequently observed in virus-infected or tumor cells, structurally unstable MHC I peptide complexes are generated, which are prone to disintegrate instead of presenting Ags to cytotoxic T cells. In this study we show that a second quality control checkpoint dependent on the serine protease proprotein convertase 7 (PC7) can rescue unstable MHC I, whereas the related convertase furin is completely dispensable. Cells with a malfunctioning PLC and silenced for PC7 have substantially reduced MHC I surface levels caused by high instability and significantly delayed surface accumulation of these molecules. Instead of acquiring stability along the secretory route, MHC I appears to get largely routed to lysosomes for degradation in these cells. Moreover, mass spectrometry analysis provides evidence that lack of PLC quality control and/or loss of PC7 expression alters the MHC I-presented peptide profile. Finally, using exogenously applied peptide precursors, we show that liberation of MHC I epitopes may directly require PC7. We demonstrate for the first time an important function for PC7 in MHC I-mediated Ag presentation.


Assuntos
Apresentação de Antígeno/imunologia , Retículo Endoplasmático/imunologia , Retículo Endoplasmático/metabolismo , Precursores Enzimáticos/fisiologia , Antígenos HLA-B/metabolismo , Peptídeos/metabolismo , Subtilisinas/fisiologia , Sequência de Aminoácidos , Animais , Apresentação de Antígeno/genética , Linhagem Celular , Linhagem Celular Transformada , Vesículas Citoplasmáticas/enzimologia , Vesículas Citoplasmáticas/imunologia , Vesículas Citoplasmáticas/metabolismo , Retículo Endoplasmático/enzimologia , Precursores Enzimáticos/antagonistas & inibidores , Precursores Enzimáticos/genética , Complexo de Golgi/enzimologia , Complexo de Golgi/imunologia , Complexo de Golgi/metabolismo , Antígeno HLA-A2/metabolismo , Antígeno HLA-B51 , Células Hep G2 , Humanos , Dados de Sequência Molecular , Peptídeos/imunologia , Ligação Proteica/imunologia , Estabilidade Proteica , Transporte Proteico/imunologia , Interferência de RNA/imunologia , Ratos , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz , Subtilisinas/antagonistas & inibidores , Subtilisinas/genética
18.
Eur J Immunol ; 39(9): 2371-6, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19701894

RESUMO

Tapasin is disulfide linked to ERp57 within the peptide loading complex. In cell-free assays, a soluble variant of the tapasin/ERp57 dimer recruits MHC class I molecules and promotes peptide binding to them, whereas soluble tapasin alone does not. Here we show that within cells, tapasin conjugation with ERp57 is as critical as its integration into the membrane for efficient MHC class I assembly, surface expression, and Ag presentation to CD8(+) T cells. Elimination of both of these properties severely compromises tapasin function, in keeping with predictions from in vitro studies.


Assuntos
Apresentação de Antígeno/imunologia , Membrana Celular/imunologia , Antígenos de Histocompatibilidade Classe I/metabolismo , Proteínas de Membrana Transportadoras/metabolismo , Isomerases de Dissulfetos de Proteínas/metabolismo , Linfócitos T Citotóxicos/imunologia , Linhagem Celular , Membrana Celular/metabolismo , Antígenos de Histocompatibilidade Classe I/imunologia , Humanos , Proteínas de Membrana Transportadoras/imunologia , Ligação Proteica/imunologia , Isomerases de Dissulfetos de Proteínas/imunologia , Linfócitos T Citotóxicos/metabolismo
19.
J Immunol ; 179(9): 5717-27, 2007 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-17947644

RESUMO

Tapasin organizes the peptide-loading complex (PLC) by recruiting peptide-receptive MHC class I (MHC-I) and accessory chaperones to the N-terminal regions of the TAP subunits TAP1 and TAP2. Despite numerous studies have shown that the formation of the PLC is essential to facilitate proper MHC-I loading, the molecular architecture of this complex is still highly controversial. We studied the stoichiometry of the PLC by blue native-PAGE in combination with Ab-shift assays and found that TAP/tapasin complexes exist at steady state as a mixture of two distinct oligomers of 350 and 450 kDa. Only the higher m.w. complex contains MHC-I and disulfide-linked tapasin/ER60 conjugates. Moreover, we show for the first time to our knowledge that the fully assembled PLC comprises two tapasin, two ER60, but only one complex of MHC-I and calreticulin. Based hereon we postulate that the TAP subunits alternate in the recruitment and loading of a single MHC-I.


Assuntos
Transportadores de Cassetes de Ligação de ATP/metabolismo , Antígenos de Histocompatibilidade Classe I/metabolismo , Peptídeos/metabolismo , Membro 2 da Subfamília B de Transportadores de Cassetes de Ligação de ATP , Membro 3 da Subfamília B de Transportadores de Cassetes de Ligação de ATP , Transportadores de Cassetes de Ligação de ATP/genética , Processamento Alternativo/genética , Sítios de Ligação , Calreticulina/metabolismo , Linhagem Celular , Dimerização , Dissulfetos/metabolismo , Humanos , Proteínas de Membrana Transportadoras/metabolismo , Chaperonas Moleculares/metabolismo , Ligação Proteica , Isomerases de Dissulfetos de Proteínas/metabolismo , Fosfolipases Tipo C/metabolismo
20.
Infect Immun ; 75(11): 5105-17, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17724071

RESUMO

The intracellular survival of the bacterial pathogen Chlamydia trachomatis depends on protein synthesis by the microbe soon after internalization. Pharmacologic inhibition of bacterial translation inhibits early trafficking of the parasitophorous vacuole (inclusion) to the microtubule-organizing center (MTOC) and promotes its fusion with lysosomes, which is normally blocked by Chlamydia. Depletion of cellular tryptophan pools by gamma interferon-inducible indoleamine-2,3-dioxygenase (IDO) is believed to be the major innate immune mechanism controlling C. trachomatis infection in human cells, an action to which the bacteria can respond by converting into a nonreplicating but highly reactivatable persistent state. However, whether severe IDO-mediated tryptophan starvation can be sufficient to fully arrest the chlamydial life cycle and thereby counteract the onset of persistence is unknown. Here we demonstrate that at low exogenous tryptophan concentrations a substantial fraction of C. trachomatis bacteria fail to traffic to the MTOC or to switch into the conventional persistent state in gamma interferon-induced human cells. The organisms stay scattered in the cell periphery, do not retain infectivity, and display only low transcriptional activity. Importantly, the rate at which these aberrant Chlamydia bacteria become reactivated upon replenishment of cellular tryptophan pools is substantially lower. Thus, severe tryptophan depletion in cells with high IDO activity affects chlamydial development more rigorously than previously described.


Assuntos
Chlamydia trachomatis/imunologia , Triptofano/metabolismo , Chlamydia trachomatis/metabolismo , Chlamydia trachomatis/patogenicidade , Citoplasma/microbiologia , Expressão Gênica/imunologia , Células HeLa , Humanos , Indolamina-Pirrol 2,3,-Dioxigenase/metabolismo , Interferon gama/imunologia , Centro Organizador dos Microtúbulos/microbiologia , RNA Bacteriano/biossíntese , RNA Mensageiro/biossíntese , Transcrição Gênica/imunologia , Virulência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...